Paradox Of China Biotech And What Lies Ahead In 2023
Growth Possible Without Strong Domestic Market?
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
You may also be interested in...
Chinese Language Podcast: 集采, ADC交易, 基因编辑出口和中国生物制药内在矛盾
Recent major ADC deals, volume-based procurement (Jicai), China’s plan to ban gene-editing technology exports and the biotech paradox in China are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key aspects to watch and the implications for major players as well as the wider pharma sector.
China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.